mk 0663 has been researched along with isomethyleugenol in 1 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (isomethyleugenol) | Trials (isomethyleugenol) | Recent Studies (post-2010) (isomethyleugenol) |
---|---|---|---|---|---|
549 | 173 | 265 | 33,847 | 127 | 11,831 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
1 other study(ies) available for mk 0663 and isomethyleugenol
Article | Year |
---|---|
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |